NCT06868732 2026-03-30
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1 Recruiting
Clinical Trials
5 trialsNCT05364073 2026-03-13
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
ArriVent BioPharma, Inc.
Phase 1 Active not recruiting
NCT04858958 2025-11-19
FAVOUR
Allist Pharmaceuticals, Inc.
Phase 1 Active not recruiting
NCT02973763 2025-04-03
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer
Allist Pharmaceuticals, Inc.
Phase 1 Terminated
NCT04958967 2025-03-14
Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation
Allist Pharmaceuticals, Inc.
Phase 1 Withdrawn